Clinical Trials Logo

Clinical Trial Summary

Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specific to these pathways have been developed and shown to be effective in treating cancer. This study will describe the effectiveness of (i) 48 weeks of alpelisib therapy for participants with slow-flow vascular malformations and a gene mutation in one of these signalling pathways (module 1) and (ii) 48 weeks of mirdametinib therapy for participants with fast-flow vascular malformations and a gene mutations in the other signalling pathway (module 2).


Clinical Trial Description

TARGET-VM is a modular open-label, signal seeking, phase II trial of targeted therapies for patients with vascular malformations. Patients with vascular malformations which are refractory to standard therapies, or in whom standard therapy is not appropriate, are potentially eligible for the clinical trial. Vascular malformations will be classified as slow-flow or fast-flow lesions using established clinical criteria. Genetic testing to identify causative variants in genes affecting the phosphoinositide 3-kinase (PI3K) signalling pathway for slow-flow vascular malformations or the Mitogen-Activated Protein Kinase (MAPK) signalling pathway for fast-flow vascular malformations must be performed using research protocols or commercial testing assays that are external to this clinical trial. The study consists of individual modules, each evaluating the clinical efficacy of 48 weeks of targeted therapy. The treatment modules are: 1. Module 1 - Treatment for slow-flow vascular malformations Eligible patients with slow-flow vascular malformations with an identified causative variant in the PI3K signalling pathway will receive alpelisib, an oral alpha-specific PI3-kinase inhibitor for a total duration of 48 weeks as monotherapy (treatment period), followed by 24 weeks of follow-up (follow-up period). 2. Module 2 - Treatment for fast-flow vascular malformations Eligible patients with fast-flow vascular malformations with an identified causative variant in the MAPK signalling pathway will receive mirdametinib, an investigational oral MEK inhibitor for a total duration of 48 weeks as monotherapy (treatment period), followed by 24 weeks of follow-up (follow-up period). TARGET-VM will be conducted only in Victoria, Australia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05983159
Study type Interventional
Source Murdoch Childrens Research Institute
Contact Michelle de Silva, PhD
Phone +61399366109
Email michelle.desilva@vcgs.org.au
Status Not yet recruiting
Phase Phase 2
Start date August 2024
Completion date December 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03306836 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 N/A
Recruiting NCT03306823 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1 N/A
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Recruiting NCT02042326 - Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations Phase 2
Recruiting NCT05484245 - Sonography-guided Resection of Brain Mass Lesions N/A
Recruiting NCT05484219 - Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations N/A
Recruiting NCT05477680 - Intraoperative Brain Shift Calculation Study N/A
Completed NCT03656211 - Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation
Completed NCT04246125 - Patient Skin Dose in Interventional Radiology
Recruiting NCT02879071 - Long Term Follow-up After Embolization of Brain Arteriovenous Malformations
Terminated NCT01801488 - Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm N/A
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Recruiting NCT02098252 - Treatment of Brain AVMs (TOBAS) Study N/A
Completed NCT02378883 - Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study N/A
Completed NCT00783523 - Influence of MMP on Brain AVM Hemorrhage Phase 1
Recruiting NCT05276934 - Brain Imaging After Non-traumatic Intracranial Hemorrhage (SAVEBRAINPWI)
Recruiting NCT03031873 - Evaluation of Susceptibility-weighted Magnetic Resonance Imaging and 4d-time-resolved Magnetic Resonance Angiography in Brain Arteriovenous Malformations N/A
Withdrawn NCT02079818 - Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System Phase 4
Completed NCT01381952 - Image Quality and Radiation Dose in Angiography N/A
Active, not recruiting NCT05418816 - SelfWrap-Assisted Arteriovenous Fistulas N/A